|News Event - American Physician Scientist Association|
APSA interactive session with cancer pioneer Dr. Brian Druker
APSA is excited to announce our spring 2017 keynote interactive session with Dr. Brian Druker, an icon in oncology and precision medicine. From David Hungerford and Peter Nowell’s discovery of the Philidelphia chromosome, to Janet Rowley’s identification of how it leads to the creation of the BCR-ABL oncogene, and ultimately Brain Druker’s clinical development of imatinib, a tyrosine kinase inhibitor targeted to the oncogene, the history of the modern treatment of chronic myelogenous leukemia (CML) represents many firsts in the understanding and treatment of cancer. Dr. Druker’s research led to the development of imatinib, the first clinically approved drug specifically targeted the molecular defect of a cancer. Imatinib transformed CML from a devastating and fatal cancer to a disease that can be held in long-term remission with a well-tolerated oral medication. For this monumental contribution to medicine, Dr. Druker has received numerous prestigious awards including the 2009 Lasker-DeBakey Award for clinical medical research. Dr. Druker is an elected member of the National Academy of Science and an investigator of the Howard Hughes Medical Institute. He currently serves as director of the Knight Cancer Institute at Oregon Health & Science University and his current research is focused on applying precision medicine to the early detection of cancer.
Dr. Druker is a prototypal example of a physician scientist and all that can be achieved in a career in medicine and science. Don’t miss this opportunity to hear the story of imatinib from Dr. Druker himself as well as hear his advice for success as a physician scientist!
Please join us on March 22, 2017 at 5:00pm EDT. Join the webinar online or dial in to participate: